The objective of this study was to explore the safety and clinical effects of amisulpride in children and adolescents with psychiatric disorders.
Methods:
This case series included six patients, aged 11 to 19 years, diagnosed with affective disorder, autism, anxiety, psychosis, and obsessive-compulsive disorder, and treated with amisulpride at doses ranging from 100 to 400 mg per day.
Results:
Amisulpride appeared to reduce psychotic and behavioral symptoms. Observed side effects included increased appetite, weight gain, sedation, and mild extrapyramidal symptoms.
Conclusion:
Amisulpride may have promise for study and future use in children and adolescents with psychiatric disorders and severe symptoms.
Get full access to this article
View all access options for this article.
References
1.
Cevher BiniciN, TopalZ, Demir SamurcuN, et al.Response of catatonia to amisulpride and lorazepam in an adolescent with schizophrenia. J Child Adolesc Psychopharmacol, 2018; 28(2):151–152.
2.
CurranMP, PerryCM. Amisulpride: A review of its use im the management of schizophrenia. Drugs, 2001; 61(14):2123–2150.
3.
DollfusS, PetitM, GarnierJP, et al.Catecholamines in autistic disorder: Effects of amisulpride and bromocriptine in a controlled crossover study. J Child Adolesc Psychopharmacol, 1993; 3(3):145–156.
HadryśT, RymaszewskaJ. Amisulpride—is it as all other medicines or is it different? An update. Psychiatr Pol, 2020; 54(5):977–989.
6.
JuruenaMF, SenaEP, OliveiraIR. Safety and tolerability of antipsychotics: Focus on amisulpride. Drug Healthc Patient Saf, 2010; 2:205–211.
7.
KahnRS, Winter van RossumI, LeuchtS, et al.;OPTiMiSE study group. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): A three-phase switching study. Lancet Psychiatry, 2018; 5(10):797–807.
8.
LecrubierY. Amisulpride: Progress and outcomes. Curr Med Res Opin, 2002; 18(sup3):s18–s22.
9.
LeuchtS, CiprianiA, SpineliL, et al.Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. Lancet, 2013; 382(9896):951–962.
10.
LeuchtS, WagenpfeilS, HamannJ, et al.Amisulpride is an “atypical” antipsychotic associated with low weight gain. Psychopharmacology (Berl), 2004; 173(1–2):112–115.
11.
LinCC, BaiYM, WangYC, et al.Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics. J Clin Psychopharmacol, 2009; 29(6):529–536.
12.
LinCL, ShiahIS, YehCB, et al.Amisulpride related tic-like symptoms in an adolescent schizophrenic. Prog Neuropsychopharmacol Biol Psychiatry, 2006; 30(1):144–146.
13.
MandalN, SinghOM, SenS. Extrapyramidal side effects with low doses of amisulpride. Indian J Psychiatry, 2014; 56(2):197–199.
14.
MetinÖ, YaziciK, TotS, et al.Amisulpride augmentation in treatment resistant obsessive-compulsive disorder: An open trial. Hum Psychopharmacol, 2003; 18(6):463–467.
15.
NesvågR, HartzI, BramnessJG, et al.Mental disorder diagnoses among children and adolescents who use antipsychotic drugs. Eur Neuropsychopharmacol, 2016; 26(9):1412–1418.
16.
PeuskensJ, BechP, MöllerHJ, et al.Amisulpride vs. risperidone in the treatment of acute exacerbation of schizophrenia. Amisulpride study group. Psychiatry Res, 1999; 88(2):107–117.
17.
SmylaN, KochT, EberhartLHJ, et al.An overview of intravenous amisulpride as a new therapeutic option for the prophylaxis and treatment of postoperative nausea and vomiting. Expert Opin Pharmacother, 2020; 21(5):517–522.
18.
TorenP, LaorN, WeizmanA. Use of atypical neuroleptics in child and adolescent psychiatry. J Clin Psychiatry, 1998; 59(12):644–656.
19.
TuncturkM, ErmisC, SaglamY, et al.When to use amisulpride in adolescents. J Clin Psychopharmacol, 2022; 42(3):247–253.
20.
Varol TasF, GuvenirT. Amisulpride treatment of adolescent patients with schizophrenia or schizo-affective disorders. Eur Child Adolesc Psychiatry, 2009; 18(8):511–513.
